# Paul Klingenstein

> Paul Klingenstein is a Series B investor at Aberdare Ventures backing Biotechnology. See 15 investments, check sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: [Aberdare Ventures](https://shizune.co/investors/profile/aberdare-ventures)
- Location: San Francisco, United States
- Total investments: 15
- Last investment: Jun 2013
- Lead investor: 0%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/paul-klingenstein-75378773

Paul Klingenstein is a Series B investor at Aberdare Ventures in San Francisco focused on Biotechnology and Health Care. Paul H. Klingenstein has served as a member of our board of directors since October 2005. Mr. Klingenstein has been a venture capital investor for most of his professional career. Beginning at Warburg, Pincus in the early 1980s, he joined Accel Partners in 1986 and helped, through the next decade, to build a leading venture capital firm.After a brief period as an advisor to the Rockefeller Foundation, he formed Aberdare Ventures in 1999, and has served as a Managing Partner since that time. During this period, he has invested in more than 50 companies, the majority of which are now public, or have been merged into public companies. These investments comprise mostly early-stage domestic businesses, but also include later-stage, public, and non-U.S. companies, and management buyouts. Mr. Klingenstein currently serves on the boards of directors of Anacor Pharmaceuticals, Aviir, Clovis Oncology, Elation ERM, EnteroMedics, and MC10, Inc. He has previously served on the boards of Ablation Frontiers, Ample Medical, Aviron, EP Technologies, Glycomed, Idun Pharmaceuticals, Isis Pharmaceuticals, Nevro Corporation, Pharmion, Posit Science, VertiFlex, U.S. Behavioral Health Viagene, and Xomed Surgical Products. Mr. Klingenstein is also serving as Chairman of the Board of the International AIDS Vaccine Initiative and is a board member of the MacArthur Foundation. He has served on the boards of various educational and non-profit institutions, including the African Wildlife Foundation, Juma Ventures, Marin Country Day School, the Taft School, and the University of California Berkeley School of Public Health. He holds an A.B. from Harvard College and an M.B.A. from Stanford University. Mr. Klingenstein's extensive experience as a venture capital investor in over 50 companies in the biotechnology and pharmaceuticals industries, as well as his experience as a director for numerous public companies, contributed to our board of directors' conclusion that he should serve as a director of our company.

## Contacts

5 contacts available for Paul Klingenstein: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/paul-klingenstein?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 27% |
| Health Care | 3 | 20% |
| Pharmaceutical | 3 | 20% |
| Health Diagnostics | 2 | 13% |
| Fitness | 1 | 7% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 27% |
| Funding Round | 2 | 13% |
| Series A | 1 | 7% |
| Series C | 1 | 7% |
| Series E | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aviir | Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development andadvanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management. | $10M | Series B | Jun 21, 2013 | http://www.aviir.com |
| Aviir | Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development andadvanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management. | $10M | Series B | Feb 12, 2013 | http://www.aviir.com |
| Aviir | Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development andadvanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management. | $10M |  | Dec 20, 2011 | http://www.aviir.com |
| Nevro | Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza systemis the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. |  | Series B | Jul 19, 2011 | http://www.nevro.com |
| Aviir | Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development andadvanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management. | $3M |  | Jun 21, 2011 | http://www.aviir.com |
| Posit Science | Posit Science helps people be at their best throughout their lives by providing brain training programs that are clinically proven to improve cognitive performance. Posit Science's brain training programs build on breakthroughs in the science of brain plasticity–the ability of the brain to change itself at any age–to improve the speed andaccuracy of brain information processing, and so improve cognitive function and real-world performance.Posit Science Corporation was formerly known as Neuroscience Solutions Corporation and changed its name in January, 2005. The company was founded in 2002 and is headquartered in San Francisco, California. | $3.1M |  | Mar 31, 2011 | http://www.brainhq.com |
| Conatus Pharmaceuticals | Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and todate its development has been the primary focus of the Company. | $20M | Series B | Feb 11, 2011 | http://www.conatuspharma.com |
| Aviir | Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development andadvanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management. | $4.2M |  | Jan 15, 2010 | http://www.aviir.com |
| Aviir | Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development andadvanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management. | $1M |  | Oct 19, 2009 | http://www.aviir.com |
| Posit Science | Posit Science helps people be at their best throughout their lives by providing brain training programs that are clinically proven to improve cognitive performance. Posit Science's brain training programs build on breakthroughs in the science of brain plasticity–the ability of the brain to change itself at any age–to improve the speed andaccuracy of brain information processing, and so improve cognitive function and real-world performance.Posit Science Corporation was formerly known as Neuroscience Solutions Corporation and changed its name in January, 2005. The company was founded in 2002 and is headquartered in San Francisco, California. | $5.6M |  | Apr 27, 2009 | http://www.brainhq.com |

10 of 15 investments shown.

## Co-investors
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 9 deals together
- [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners) — VC Fund, 5 deals together
- [Merck Global Health Innovation Fund](https://shizune.co/investors/profile/merck-global-health-innovation-fund) — VC Fund, 3 deals together
- [Care Capital](https://shizune.co/investors/profile/care-capital) — VC Fund, 2 deals together
- [Rho Capital Partners](https://shizune.co/investors/profile/rho-capital-ventures) — VC Fund, 2 deals together
- [Threshold](https://shizune.co/investors/profile/threshold) — VC Fund, 2 deals together

## About Aberdare Ventures

VC Fund · San Francisco, United States

Aberdare Ventures is a venture firm that focuses on a limited number of entrepreneurial teams committed to building leading healthcare technology companies. They limit their commitments in the belief that their involvement can increase the probability of success for their portfolio companies and generate greater returns for their investors.

5 contacts available at Aberdare Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Christina Fong | Controller | https://shizune.co/investors/profile/christina-fong |
| Judy Stralka | Administrator | https://shizune.co/investors/profile/judy-stralka |
| Maureen Valentini | Bookkeeper | https://shizune.co/investors/profile/maureen-valentini |
| Mohit Kaushal | Partner | https://shizune.co/investors/profile/mohit-kaushal |
| Paul Klingenstein | Managing Partner | https://shizune.co/investors/profile/paul-klingenstein |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Paul Klingenstein invest in?

Paul Klingenstein invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Funding Round stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Paul Klingenstein?

Public channels for Paul Klingenstein include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Paul Klingenstein last invest?

The most recent investment recorded for Paul Klingenstein closed in Jun 2013. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co